Emphasizing the validity of this strategy, four of the top six targets by our ranking either already have FDA-approved therapeutics or are being clinically investigated in myeloma: BCMA (TNRFSF17 gene), TACI (TNFRSF13B), Integrin beta-7 (ITGB7), and CS-1/SLAMF7 (SLAMF7) (Fig. 2A). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.